The positivity rate was lower for EpCAM in mesotheliomas, hepatocellular carcinomas, very poorly differentiated tumors (anaplastic thyroid cancer, sarcomatoid urothelial cancer), and—to a lesser extent—in squamous cell carcinomas. Here, EPCAM is linked to mesothelioma.